New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
16:15 EDTINFIInfinity Pharmaceuticals amends PI3K-Delta, Gamma agreement with Millenium
Infinity Pharmaceuticals announced that the company has purchased an option to buy out all future potential royalty payments due to Millennium: The Takeda Oncology Company for sales in oncology of IPI-145, Infinity’s oral inhibitor of phosphoinositide-3-kinase, or PI3K-delta and PI3K-gamma. In exchange for a one-time, upfront payment of $5.0M, Infinity receives an option to terminate its obligation to pay Millennium future royalties related to the sale of IPI-145 in oncology. Infinity may exercise this option by providing written notice and payment to Millennium of a one-time exercise fee of $52.5M on or before March 31, 2015. Exercise of the option does not affect any other obligation under the Development and License Agreement, including Infinity’s obligation to pay royalties on sales of IPI-145 outside of oncology. If Infinity does not exercise the option, its royalty obligations with respect to IPI-145 in oncology will remain in effect. Assuming exercise of the option, Infinity’s obligation to pay Millennium tiered royalties, ranging from 7%-11%, on worldwide net sales of Infinity’s first two distinct PI3K product candidates will exclude worldwide net sales of IPI-145 in oncology. Infinity will remain obligated to pay milestones to Millennium for Infinity’s first two distinct PI3K product candidates that gain approval, including IPI-145. The remaining milestones comprise up to a total of $220M in success-based regulatory milestones, up to a total of $230M in commercial milestones which are due once certain sales thresholds have been met, and up to a total of $5M in development milestones.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:31 EDTINFIInfinity Pharmaceuticals reports results from Phase 1 study of duvelisib
Infinity Pharmaceuticals reported updated data from a Phase 1 monotherapy study of duvelisib, an inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma, a fatal type of blood cancer. In the study, duvelisib demonstrated an overall response rate of 72%, including a 33% complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies. In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma.
December 8, 2014
10:47 EDTINFIInfinity reports updated Phase 1 data from duvelisib study, says well tolerated
Subscribe for More Information
December 7, 2014
14:31 EDTINFIInfinity Pharmaceuticals to hold a luncheon and data presentation meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use